Stock listing

OTC:CYTOF Altamira Therapeutics Ltd. Stock

Follow Altamira Therapeutics Ltd. into a list and get an email when it puts out news.

Share price · OTC:CYTOF

$0.071 USD 0.000 (0.0%)

Close on Nov 18, 2026

Past year -21.3% · daily closes, Nov 18, 2025 – Nov 18, 2026, adjusted for splits
Day range
$0.071 – $0.071 USDNov 18, 2026
Volume
1,856 sharesNov 18, 2026
Market cap
$404,655 USDAt the close on Nov 18, 2026 · price × 5.72M shares outstanding
52-week range
$0.050 – $0.147 USDLowest and highest trades, Nov 19, 2025 – Nov 18, 2026
Traded on an average day
$351 USDMedian day 400 shares · 19 days with no trades · last 3 months, Aug 18, 2026 – Nov 18, 2026
Altamira Therapeutics Ltd. logo

Daily closes

Last 3 months, Aug 18, 2026 – Nov 18, 2026 · OTC:CYTOF · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.0710.0000.0%$0.071$0.071$0.0711,856
$0.0710.0000.0%$0.071$0.071$0.071329
$0.071-0.001-1.7%$0.071$0.071$0.071150
$0.072-0.028-28.0%$0.083$0.083$0.0722,100
$0.1000.0000.0%$0.100$0.100$0.1000
$0.1000.0000.0%$0.100$0.100$0.1000
$0.100+0.029+40.8%$0.100$0.100$0.1004,000
$0.0710.0000.0%$0.071$0.071$0.0710
$0.071-0.032-31.1%$0.071$0.071$0.0711,600
$0.103+0.033+47.1%$0.090$0.103$0.08012,200
$0.070-0.030-30.0%$0.110$0.110$0.0704,000
$0.100+0.031+44.9%$0.100$0.100$0.10020,800
$0.069-0.016-18.8%$0.069$0.069$0.0691,800
$0.0850.0000.0%$0.085$0.085$0.0850
$0.0850.0000.0%$0.085$0.085$0.0850
$0.0850.0000.0%$0.085$0.085$0.0850
$0.085-0.005-5.6%$0.085$0.085$0.0851,600
$0.0900.0000.0%$0.090$0.090$0.0900
$0.0900.0000.0%$0.090$0.090$0.0900
$0.090+0.010+12.5%$0.080$0.090$0.08065,400
$0.080+0.006+8.1%$0.080$0.080$0.0801,800
$0.074+0.012+19.4%$0.063$0.074$0.0584,400
$0.062+0.007+12.7%$0.062$0.062$0.062400
$0.055-0.014-20.3%$0.058$0.058$0.0551,800
$0.069-0.020-22.5%$0.065$0.070$0.065500
$0.0890.0000.0%$0.089$0.089$0.0890
$0.0890.0000.0%$0.089$0.089$0.0890
$0.0890.0000.0%$0.089$0.089$0.089800
$0.089+0.014+18.7%$0.070$0.089$0.0708,100
$0.0750.0000.0%$0.075$0.075$0.0750
$0.0750.0000.0%$0.075$0.075$0.0750
$0.075+0.020+36.4%$0.069$0.075$0.069200
$0.055-0.017-23.6%$0.055$0.055$0.055200
$0.0720.0000.0%$0.072$0.072$0.0720
$0.0720.0000.0%$0.072$0.072$0.0720
$0.0720.0000.0%$0.072$0.072$0.0720
$0.0720.0000.0%$0.072$0.072$0.072535
$0.072-0.017-19.1%$0.072$0.072$0.072400
$0.089+0.039+78.0%$0.089$0.089$0.089500
$0.050-0.039-43.8%$0.050$0.050$0.050300
$0.0890.0000.0%$0.089$0.089$0.0890
$0.089+0.038+74.5%$0.050$0.089$0.050500
$0.051+0.001+2.0%$0.051$0.051$0.051100
$0.050-0.021-29.6%$0.050$0.050$0.0508,000
$0.0710.0000.0%$0.071$0.071$0.0712
$0.071-0.003-4.1%$0.077$0.077$0.07112,000
$0.074+0.003+4.2%$0.071$0.074$0.06312,100
$0.0710.0000.0%$0.071$0.071$0.0712
$0.0710.0000.0%$0.089$0.089$0.06667,000
$0.0710.0000.0%$0.071$0.071$0.07128
$0.071-0.013-15.5%$0.071$0.071$0.07115,100
$0.084+0.014+20.0%$0.084$0.084$0.0846,200
$0.0700.0000.0%$0.070$0.070$0.0700
$0.0700.0000.0%$0.070$0.070$0.0700
$0.0700.0000.0%$0.070$0.070$0.0700
$0.070-0.001-1.4%$0.065$0.074$0.0653,200
$0.071+0.007+10.9%$0.070$0.071$0.0641,500
$0.0640.0000.0%$0.064$0.064$0.0642
$0.0640.0000.0%$0.064$0.064$0.064700
$0.0640.0000.0%$0.064$0.064$0.064100
$0.064-0.006-8.6%$0.064$0.064$0.0645,000

Splits

4 splits since 2018 · OTC:CYTOF · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-20Consolidation
1-for-20Consolidation
1-for-10Consolidation
Ticker
OTC:CYTOF
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

Altamira Therapeutics Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
Decks
7 decks · latest Mar 8, 2023

Valuation

Price/book 0.1× against a median of 0.2×: 3rd lowest of 8 Biotechnology companies shown. balance Jun 30, 2025 · price Nov 18, 2026

Enterprise value
$400,900 USD
P/E
Not reported
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.64

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Altamira Therapeutics Ltd. · OTC:CYTOFUS$404,655US$400,900n/an/an/a0.1×n/a0.0×0.64
Oragenics Inc. · AMEX:OGENUS$708,377−US$1.12Mn/an/an/a0.7×n/a0.4×1.47
Protagenic Therapeutics, Inc. · OTC:PTIXUS$687,879US$610,9700.1×n/an/a0.6×n/a0.0×1.21
Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABTUS$580,337−US$2.74Mn/an/an/a0.2×n/a0.0×0.46
Mushrooms, Inc. · OTC:MSRMUS$539,339US$564,177n/an/an/an/an/an/a1.24
Jaguar Health, Inc. · NASDAQ:JAGXUS$527,406−US$1.48Mn/a−0.1×n/a0.0×−181.8%0.2×3.75
NKGen Biotech Inc. · OTC:NKGNUS$391,807US$38.58Mn/an/an/an/an/an/a0.88
Vaxil Bio Ltd. · TSXV:VXLUS$319,477−US$4,0711.2×n/an/a0.4×n/a0.0×-0.16
Chimeric Therapeutics Limited · ASX:CHMUS$293,048−US$220,369n/a−0.1×n/a0.2×−262.8%2.5×n/a
CERo Therapeutics Holdings, Inc. · OTC:CEROUS$265,035−US$190,890n/an/an/an/an/an/a1.47
CDT Equity Inc. · NASDAQ:CDTUS$234,109−US$1.49Mn/an/an/a0.0×n/a0.0×1.14
Median of the othersUS$459,607−US$205,6300.7×−0.1×0.2×−222.3%0.0×1.21

Team and board

Officers

OfficerRole
Thomas MeyerChairman of the Board, Chief Executive Officer
Marcel GremaudChief Financial Officer
Covadonga PañedaChief Operating Officer
Samuel A. WicklineChief Scientific Adviser

Board

DirectorRole
Thomas MeyerChairman of the Board, Chief Executive Officer
Alain MunozDirector
Dominik LysekDirector

Events

QuarterResultsShare move
Q2 2025Aug 29, 20250.0%
Quarter to Mar 31, 2025Apr 30, 2025−12.5%
Q2 2024Sep 24, 2024+0.3%
Quarter to Sep 30, 2022Nov 17, 2022−11.4%
Quarter to Jun 30, 2022Aug 18, 2022−4.2%
Quarter to Mar 31, 2022Apr 12, 2022−30.7%
Quarter to Sep 30, 2021Nov 18, 2021−17.7%
Quarter to Jun 30, 2021Sep 8, 2021+0.4%
Quarter to Mar 31, 2021May 18, 2021+5.0%
Quarter to Dec 31, 2020Mar 31, 2021+5.9%

Open Events

Decks

Open Decks

IPO

Went public as Auris Medical Holding AG. Priced at US$6.00 a share on Aug 5, 2014.

Price
US$6.00 a share
Shares offered
9,400,000 common shares
Offering size
US$56.4 million
Underwriters' option
Up to 1,410,000 more shares
Underwriters
Jefferies, Leerink Partners, JMP Securities, Needham & Company · In the order on the cover
Shares delivered
On or about Aug 11, 2014

Steps

StepWhen
Draft sent to the SEC in confidenceMar 18, 2014
Filed publiclyJun 27, 2014
Amended 3 timesNewest Aug 8, 2014
Shares registered with an exchangeJul 29, 2014
Declared effective by the SECAug 5, 2014
Final prospectus, with the priceAug 7, 2014

Open IPO · From the cover of the final prospectus (424B4) filed Aug 7, 2014

Financials

Annual, in USD

Income statement

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue0000
Cost of revenue268.9K1.56M2.45M
Gross profit-80.6K-1.23M-2.38M
Research and development3.73M3.38M15.3M3.50M
Selling, general and administrative3.20M3.49M3.56M3.98M
Operating income-6.85M-6.58M-18.9M-7.52M
Depreciation and amortization127.1K132.8K124.5K83.5K
EBITDA-6.72M-6.45M-18.7M-7.43M
Interest expense01.12M934.0K15.4K
Income before tax-8.46M-8.09M-19.5M-6.81M
Income tax-8.29K117.9K
Net income-8.46M-4.31M-27.8M-18.7M-8.20M-6.63M-11.5M
Earnings per share, basic-2.99-8.77-610.03-498.82-14.36-1.61-6.47
Earnings per share, diluted-2.99-8.77-610.03

Balance sheet

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents998.6K733.7K16.6K1.08M
Receivables007.05K23.8K
Inventory0012.6K918.1K
Current assets1.54M1.45M1.91M4.48M
Property, plant and equipment100.0K1
Total assets8.65M9.14M6.81M21.0M
Accounts payable552.0K523.4K5.31M3.88M
Current liabilities1.16M1.06M13.9M5.32M
Total debt5.29M
Total liabilities2.09M1.47M15.8M6.71M
Shareholders' equity6.57M7.68M-8.30M14.3M
Shares outstanding4.66M1.48M59.0K37.4K570.9K4.13M1.78M

Cash flow

LineFY2024FY2023FY2022FY2021FY2019FY2018
Cash from operations-6.11M-12.8M-9.09M-15.0M
Capital spending-103.1K0-2.24M-3.64M00
Free cash flow-6.22M-11.5M-11.3M-18.6M
Cash from investing-115.3K1.61M-2.24M
Cash from financing6.51M11.8M10.3M7.24M
Dividends paid0000
Change in cash276.3K618.2K-1.04M-11.6M

Open Financials

Filings

FilingDateTypeFiled with
15-12GFeb 27, 2026Other filingsSEC
6-K · Report of a foreign issuerAug 29, 2025Current reportSEC
25-NSEJun 17, 2025Other filingsSEC
6-K · Report of a foreign issuerJun 11, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerMay 9, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 6, 2025Big-stake noticeSEC
20-F · Annual reportApr 30, 2025Annual reportSEC
6-K · Report of a foreign issuerApr 30, 2025Current reportSEC
S-8 · Registration statement for employee plansApr 4, 2025Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerMar 10, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerDec 20, 2024Current reportSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerOct 4, 2024Current reportSEC
6-K · Report of a foreign issuerSep 24, 2024Current reportSEC
6-K · Report of a foreign issuerSep 19, 2024Current reportSEC
424B4 · ProspectusSep 18, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 18, 2024Other filingsSEC
CORRESP · Letter to the SECSep 16, 2024Other filingsSEC
CORRESP · Letter to the SECSep 16, 2024Other filingsSEC
F-1/A · Registration statement, amendedSep 16, 2024Offer documentSEC
F-1/A · Registration statement, amendedSep 16, 2024Offer documentSEC
UPLOAD · Letter from the SECAug 28, 2024Other filingsSEC
F-1 · Registration statementAug 22, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 15, 2024Other filingsSEC
POS AM · Amendment to an effective registrationJul 8, 2024Offer documentSEC
20-F/A · Annual report, amendedJul 1, 2024Annual reportSEC
6-K · Report of a foreign issuerMay 16, 2024Current reportSEC
20-F/A · Annual report, amendedApr 22, 2024Annual reportSEC
EFFECT · Notice that a registration is effectiveApr 18, 2024Other filingsSEC
424B4 · ProspectusApr 17, 2024Offer documentSEC
6-K · Report of a foreign issuerApr 16, 2024Current reportSEC
UPLOAD · Letter from the SECApr 16, 2024Other filingsSEC
CORRESP · Letter to the SECApr 16, 2024Other filingsSEC
6-K · Report of a foreign issuerApr 10, 2024Current reportSEC
S-8 · Registration statement for employee plansApr 10, 2024Offer documentSEC
F-1 · Registration statementApr 10, 2024Offer documentSEC
20-F · Annual reportApr 10, 2024Annual reportSEC
SC 13D/A · Big-stake notice, amendedMar 13, 2024Big-stake noticeSEC
424B4 · ProspectusJan 22, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 22, 2024Other filingsSEC
6-K · Report of a foreign issuerJan 19, 2024Current reportSEC
424B5 · ProspectusJan 19, 2024Offer documentSEC
6-K · Report of a foreign issuerJan 19, 2024Current reportSEC
CORRESP · Letter to the SECJan 17, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 16, 2024Other filingsSEC
F-3 · Registration statementJan 8, 2024Offer documentSEC
6-K · Report of a foreign issuerDec 11, 2023Current reportSEC
6-K · Report of a foreign issuerDec 11, 2023Current reportSEC
6-K · Report of a foreign issuerDec 8, 2023Current reportSEC
6-K · Report of a foreign issuerNov 22, 2023Current reportSEC
6-K · Report of a foreign issuerNov 21, 2023Current reportSEC
6-K · Report of a foreign issuerOct 31, 2023Current reportSEC
6-K · Report of a foreign issuerOct 4, 2023Current reportSEC
6-K · Report of a foreign issuerSep 12, 2023Current reportSEC
6-K/A · Report of a foreign issuer, amendedAug 21, 2023Current reportSEC
6-K · Report of a foreign issuerJul 28, 2023Current reportSEC
6-K · Report of a foreign issuerJul 26, 2023Current reportSEC
6-K · Report of a foreign issuerJul 11, 2023Current reportSEC
424B4 · ProspectusJul 7, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 6, 2023Other filingsSEC
CORRESP · Letter to the SECJul 5, 2023Other filingsSEC
CORRESP · Letter to the SECJul 5, 2023Other filingsSEC
6-K · Report of a foreign issuerJul 3, 2023Current reportSEC
F-1/A · Registration statement, amendedJul 3, 2023Offer documentSEC
6-K · Report of a foreign issuerJun 30, 2023Current reportSEC
6-K · Report of a foreign issuerJun 27, 2023Current reportSEC
UPLOAD · Letter from the SECJun 23, 2023Other filingsSEC
F-1 · Registration statementJun 16, 2023Offer documentSEC
6-K · Report of a foreign issuerJun 15, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveJun 12, 2023Other filingsSEC
EFFECT · Notice that a registration is effectiveJun 12, 2023Other filingsSEC
424B3 · ProspectusJun 9, 2023Offer documentSEC
424B3 · ProspectusJun 9, 2023Offer documentSEC
CORRESP · Letter to the SECJun 9, 2023Other filingsSEC
CORRESP · Letter to the SECJun 9, 2023Other filingsSEC
UPLOAD · Letter from the SECJun 8, 2023Other filingsSEC
UPLOAD · Letter from the SECJun 8, 2023Other filingsSEC
F-3 · Registration statementJun 1, 2023Offer documentSEC
F-1 · Registration statementJun 1, 2023Offer documentSEC
6-K · Report of a foreign issuerMay 30, 2023Current reportSEC
6-K · Report of a foreign issuerMay 26, 2023Current reportSEC
6-K · Report of a foreign issuerMay 16, 2023Current reportSEC
20-F · Annual reportMay 16, 2023Annual reportSEC
6-K · Report of a foreign issuerMay 2, 2023Current reportSEC
NT 20-FMay 1, 2023Explanation requestSEC
SC 13D/A · Big-stake notice, amendedApr 27, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerApr 18, 2023Current reportSEC
CERT · Exchange's certificate of listingApr 17, 2023Other filingsSEC
6-K · Report of a foreign issuerApr 13, 2023Current reportSEC
RW · Request to withdraw a registrationApr 13, 2023Other filingsSEC
CERT · Exchange's certificate of listingApr 12, 2023Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeApr 11, 2023Other filingsSEC
FWP · Free writing prospectusApr 11, 2023Offer documentSEC
6-K · Report of a foreign issuerApr 3, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveApr 3, 2023Other filingsSEC
CORRESP · Letter to the SECMar 31, 2023Other filingsSEC
CORRESP · Letter to the SECMar 31, 2023Other filingsSEC
CORRESP · Letter to the SECMar 31, 2023Other filingsSEC
CORRESP · Letter to the SECMar 31, 2023Other filingsSEC
F-1/A · Registration statement, amendedMar 27, 2023Offer documentSEC
CORRESP · Letter to the SECMar 23, 2023Other filingsSEC
CORRESP · Letter to the SECMar 23, 2023Other filingsSEC
CORRESP · Letter to the SECMar 23, 2023Other filingsSEC
CORRESP · Letter to the SECMar 23, 2023Other filingsSEC
FWP · Free writing prospectusMar 23, 2023Offer documentSEC
F-1/A · Registration statement, amendedMar 22, 2023Offer documentSEC
CORRESP · Letter to the SECMar 17, 2023Other filingsSEC
CORRESP · Letter to the SECMar 17, 2023Other filingsSEC
CORRESP · Letter to the SECMar 17, 2023Other filingsSEC
CORRESP · Letter to the SECMar 17, 2023Other filingsSEC
CORRESP · Letter to the SECMar 13, 2023Other filingsSEC
CORRESP · Letter to the SECMar 13, 2023Other filingsSEC
F-1/A · Registration statement, amendedMar 13, 2023Offer documentSEC
FWP · Free writing prospectusMar 9, 2023Offer documentSEC
6-K · Report of a foreign issuerMar 9, 2023Current reportSEC
FWP · Free writing prospectusMar 8, 2023Offer documentSEC
F-1/A · Registration statement, amendedMar 7, 2023Offer documentSEC
F-1/A · Registration statement, amendedMar 1, 2023Offer documentSEC
F-1/A · Registration statement, amendedFeb 28, 2023Offer documentSEC
CORRESP · Letter to the SECFeb 28, 2023Other filingsSEC
UPLOAD · Letter from the SECFeb 24, 2023Other filingsSEC
6-K · Report of a foreign issuerFeb 17, 2023Current reportSEC
F-1 · Registration statementFeb 16, 2023Offer documentSEC
6-K · Report of a foreign issuerJan 27, 2023Current reportSEC
6-K · Report of a foreign issuerJan 24, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedJan 18, 2023Big-stake noticeSEC
424B4 · ProspectusDec 28, 2022Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 28, 2022Other filingsSEC
UPLOAD · Letter from the SECDec 22, 2022Other filingsSEC
CORRESP · Letter to the SECDec 22, 2022Other filingsSEC
6-K · Report of a foreign issuerDec 19, 2022Current reportSEC
F-1 · Registration statementDec 16, 2022Offer documentSEC
6-K · Report of a foreign issuerDec 5, 2022Current reportSEC
6-K · Report of a foreign issuerNov 30, 2022Current reportSEC
6-K · Report of a foreign issuerNov 9, 2022Current reportSEC
6-K · Report of a foreign issuerOct 24, 2022Current reportSEC
6-K · Report of a foreign issuerOct 24, 2022Current reportSEC
EFFECT · Notice that a registration is effectiveOct 3, 2022Other filingsSEC
6-K · Report of a foreign issuerSep 29, 2022Current reportSEC
UPLOAD · Letter from the SECSep 29, 2022Other filingsSEC
CORRESP · Letter to the SECSep 29, 2022Other filingsSEC
F-3 · Registration statementSep 23, 2022Offer documentSEC
SC 13D/A · Big-stake notice, amendedSep 13, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerSep 12, 2022Current reportSEC
6-K · Report of a foreign issuerAug 30, 2022Current reportSEC
6-K · Report of a foreign issuerAug 26, 2022Current reportSEC
6-K · Report of a foreign issuerJun 27, 2022Current reportSEC
6-K · Report of a foreign issuerJun 13, 2022Current reportSEC
6-K · Report of a foreign issuerJun 7, 2022Current reportSEC
6-K · Report of a foreign issuerMay 19, 2022Current reportSEC
6-K · Report of a foreign issuerMay 17, 2022Current reportSEC
424B3 · ProspectusMay 17, 2022Offer documentSEC
SC 13D/A · Big-stake notice, amendedMay 13, 2022Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveApr 26, 2022Other filingsSEC
424B3 · ProspectusApr 25, 2022Offer documentSEC
CORRESP · Letter to the SECApr 22, 2022Other filingsSEC
UPLOAD · Letter from the SECApr 20, 2022Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 20, 2022Other filingsSEC
6-K · Report of a foreign issuerApr 18, 2022Current reportSEC
F-3 · Registration statementApr 14, 2022Offer documentSEC
POS AM · Amendment to an effective registrationApr 14, 2022Offer documentSEC
20-F · Annual reportApr 12, 2022Annual reportSEC
6-K · Report of a foreign issuerMar 4, 2022Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 18, 2022Other filingsSEC
424B3 · ProspectusFeb 17, 2022Offer documentSEC
CORRESP · Letter to the SECFeb 15, 2022Other filingsSEC
UPLOAD · Letter from the SECFeb 14, 2022Other filingsSEC
F-1 · Registration statementFeb 8, 2022Offer documentSEC
6-K · Report of a foreign issuerFeb 8, 2022Current reportSEC
6-K · Report of a foreign issuerDec 16, 2021Current reportSEC
EFFECT · Notice that a registration is effectiveDec 9, 2021Other filingsSEC
424B5 · ProspectusDec 8, 2021Offer documentSEC
CORRESP · Letter to the SECDec 7, 2021Other filingsSEC
UPLOAD · Letter from the SECNov 24, 2021Other filingsSEC
EFFECT · Notice that a registration is effectiveNov 24, 2021Other filingsSEC
F-3 · Registration statementNov 16, 2021Offer documentSEC
POS AM · Amendment to an effective registrationNov 16, 2021Offer documentSEC
6-K · Report of a foreign issuerSep 8, 2021Current reportSEC
6-K · Report of a foreign issuerJul 23, 2021Current reportSEC
6-K · Report of a foreign issuerJul 21, 2021Current reportSEC
6-K · Report of a foreign issuerJun 16, 2021Current reportSEC
EFFECT · Notice that a registration is effectiveJun 8, 2021Other filingsSEC
6-K · Report of a foreign issuerJun 3, 2021Current reportSEC
POS AM · Amendment to an effective registrationJun 2, 2021Offer documentSEC
POS AM · Amendment to an effective registrationJun 2, 2021Offer documentSEC
SC 13D/A · Big-stake notice, amendedMay 21, 2021Big-stake noticeSEC
6-K · Report of a foreign issuerMay 17, 2021Current reportSEC
6-K · Report of a foreign issuerApr 16, 2021Current reportSEC
6-K · Report of a foreign issuerApr 13, 2021Current reportSEC
6-K · Report of a foreign issuerMar 31, 2021Current reportSEC
20-F · Annual reportMar 31, 2021Annual reportSEC
6-K · Report of a foreign issuerMar 12, 2021Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2021Big-stake noticeSEC
6-K · Report of a foreign issuerJan 15, 2021Current reportSEC
424B5 · ProspectusJan 15, 2021Offer documentSEC
S-8 · Registration statement for employee plansJan 15, 2021Offer documentSEC
6-K · Report of a foreign issuerDec 10, 2020Current reportSEC
SC 13D/A · Big-stake notice, amendedDec 7, 2020Big-stake noticeSEC

This page holds 200 of 518 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Altamira Therapeutics Ltd.’s releases

Common shares
5,715,472
Fully diluted
5,715,472

Fully diluted

LineShares
Common shares5,715,472

Share count over time

CountShares
Nov 22, 20265,715,472

Open Cap table

Shareholders

HolderSharesChange vs Jun 30Filed
LRI Investments, LLC1NewNov 16, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alain MunozDirector · Since at least Nov 5, 2026
Covadonga PañedaChief Operating Officer · Since at least Nov 4, 2026
Dominik LysekDirector · Since at least Nov 5, 2026
Marcel GremaudChief Financial Officer · Since at least Nov 4, 2026
Samuel A. WicklineChief Scientific Adviser · Since at least Nov 4, 2026
Thomas MeyerChairman of the Board, Chief Executive Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Altamira Therapeutics Ltd.